A team of researchers developed LeukoLike Vectors (LLV), synthetic particles coated with leukocyte membranes, which mimic the functions of white blood cells. These particles can evade the immune system, cross biological barriers, and deliver drugs to target tissues. The study shows that LLV can avoid rapid clearance by the immune system, communicate with endothelial cells, and transport drugs across inflamed endothelium. LLV also showed enhanced circulation time and improved tumor accumulation in vivo. Biological barriers regulate the movement of foreign materials, and endothelial cells play a key role in identifying and capturing potential hazards. Systemically injected drugs and particles are often tagged by proteins (opsonization) for removal by the immune system. To function properly, systemic agents must avoid immune clearance, navigate past vascular barriers, and localize at target tissues. Encapsulating drugs in nanoparticles improves their half-life, site-specific targeting, and therapeutic efficacy. Optimization of particle size, shape, and surface charge enhances passive tumor targeting. Surface modification with polyethylene glycol (PEG) improves biodistribution, while bioconjugation of targeting molecules enhances delivery to specific cells. Recent efforts have focused on multistage vectors that decouple these functions. However, particle-based drug delivery has not yet reached its full potential. Avoiding opsonization and non-specific clearance remains a challenge, and PEG cannot completely prevent clearance. Particles with longer circulation times show increased tumor accumulation in tumors with fenestrated endothelia. However, not all tumors have increased vessel permeability, making vascular barrier negotiation essential for effective drug delivery. "Biomimetic camouflage" strategies are gaining popularity to overcome vascular barriers. Virus-based carriers, targeted protocells, and bio-nano hybrid systems have been proposed. LLV, produced by camouflaging NPS particles with leukocyte membranes, can avoid opsonization, delay uptake by the mononuclear phagocyte system, and facilitate drug transport across endothelium while eluding the lysosomal pathway. LLV showed reduced phagocytosis and enhanced adhesion to inflamed endothelium. They were able to cross a reconstructed endothelial monolayer, increasing permeability. LLV also showed enhanced tumor accumulation in mice, with improved circulation time and tumor targeting. The study concludes that LLV can successfully transport therapeutic payloads through the endothelium and release them in the target tissue. Unlike conventional nanocarriers, LLV can recognize and bind tumor endothelium in an active, non-destructive manner. This suggests that future tumor-targeting drug carriers may avoid the need for fenestrated endothelium and reduce concerns about particle-induced injury to endothelial barrier function.A team of researchers developed LeukoLike Vectors (LLV), synthetic particles coated with leukocyte membranes, which mimic the functions of white blood cells. These particles can evade the immune system, cross biological barriers, and deliver drugs to target tissues. The study shows that LLV can avoid rapid clearance by the immune system, communicate with endothelial cells, and transport drugs across inflamed endothelium. LLV also showed enhanced circulation time and improved tumor accumulation in vivo. Biological barriers regulate the movement of foreign materials, and endothelial cells play a key role in identifying and capturing potential hazards. Systemically injected drugs and particles are often tagged by proteins (opsonization) for removal by the immune system. To function properly, systemic agents must avoid immune clearance, navigate past vascular barriers, and localize at target tissues. Encapsulating drugs in nanoparticles improves their half-life, site-specific targeting, and therapeutic efficacy. Optimization of particle size, shape, and surface charge enhances passive tumor targeting. Surface modification with polyethylene glycol (PEG) improves biodistribution, while bioconjugation of targeting molecules enhances delivery to specific cells. Recent efforts have focused on multistage vectors that decouple these functions. However, particle-based drug delivery has not yet reached its full potential. Avoiding opsonization and non-specific clearance remains a challenge, and PEG cannot completely prevent clearance. Particles with longer circulation times show increased tumor accumulation in tumors with fenestrated endothelia. However, not all tumors have increased vessel permeability, making vascular barrier negotiation essential for effective drug delivery. "Biomimetic camouflage" strategies are gaining popularity to overcome vascular barriers. Virus-based carriers, targeted protocells, and bio-nano hybrid systems have been proposed. LLV, produced by camouflaging NPS particles with leukocyte membranes, can avoid opsonization, delay uptake by the mononuclear phagocyte system, and facilitate drug transport across endothelium while eluding the lysosomal pathway. LLV showed reduced phagocytosis and enhanced adhesion to inflamed endothelium. They were able to cross a reconstructed endothelial monolayer, increasing permeability. LLV also showed enhanced tumor accumulation in mice, with improved circulation time and tumor targeting. The study concludes that LLV can successfully transport therapeutic payloads through the endothelium and release them in the target tissue. Unlike conventional nanocarriers, LLV can recognize and bind tumor endothelium in an active, non-destructive manner. This suggests that future tumor-targeting drug carriers may avoid the need for fenestrated endothelium and reduce concerns about particle-induced injury to endothelial barrier function.